BMS 561392

Drug Profile

BMS 561392

Alternative Names: BMS-561392; DPC 333

Latest Information Update: 17 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antirheumatics; Quinolines; Small molecules
  • Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 17 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
  • 17 Jan 2008 Discontinued - Phase-II for Rheumatoid arthritis in North America (PO)
  • 17 Jan 2008 Discontinued - Preclinical for Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top